NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has been granted expanded use in Europe for its Dako PD-L1 IHC 28-8 pharmDx test, a companion diagnostic for Bristol-Myers Squibb's cancer drug Opdivo (nivolumab).

According to Agilent, the test is now approved for identifying patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy. The test is already approved in Europe for tumor cell PD-L1 expression for non-squamous non-small-cell lung cancer (ns-NSCLC) and melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.